Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
43.52
+0.94 (2.21%)
Mar 5, 2026, 4:08 PM HKT
31.48%
Market Cap 51.72B
Revenue (ttm) 7.17B
Net Income (ttm) 669.02M
Shares Out n/a
EPS (ttm) 0.78
PE Ratio 77.31
Forward PE 37.90
Dividend 0.32 (0.71%)
Ex-Dividend Date Jun 12, 2025
Volume 1,130,168
Average Volume 1,625,970
Open 43.12
Previous Close 42.58
Day's Range 43.04 - 44.42
52-Week Range 22.30 - 60.60
Beta 0.82
RSI 37.43
Earnings Date Mar 31, 2026

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,185
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3347
Full Company Profile

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY Financial Statements

News

Hangzhou Tigermed Consulting Co., Ltd (HNGZY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

2026-01-16. The following slide deck was published by Hangzhou Tigermed Consulting Co., Ltd in conjunction with this event.

6 weeks ago - Seeking Alpha